How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

690 results for

Dysuria in Children

Latest & greatest

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

581. Specific Poisons

with 60–250 mL (2–8 oz) in adults or 8–10 mL (2 tsp) in children Latency period 12–18 h Headache, weakness, leg cramps, vertigo, seizures, retinal injury, dimmed vision, metabolic acidosis, decreased respiration Fomepizole (15 mg/kg, then 10 mg/kg q 12 h); alternatively, 10% ethanol/5% D/W IV with an initial loading dose of 10 mL/kg over 1 h, then 1–2 mL/kg/h to maintain a blood ethanol level of 100 mg/dL (22 mmol/L) Hemodialysis (which is definitive treatment) Aldrin See Chlorinated and other (...) — Antihistamines Anticholinergic symptoms (eg, tachycardia, hyperthermia, mydriasis, warm and dry skin, urinary retention, ileus, delirium) For diagnostic or therapeutic trial or for treatment of severe symptoms refractory to sedation (C aution : Seizures—see Physostigmine ), consideration of physostigmine 0.5–2.0 mg in adults or 0.02 mg/kg in children IV (slowly) Antihyperglycemic drugs, oral See Hypoglycemic drugs, oral — Antimony Stibophen Tartar emetic Throat constriction, dysphagia, burning GI pain

2013 Merck Manual (19th Edition)

582. Vaginal Itching and Discharge

Vaginal Birth Video How to Deliver a Baby in Breech Presentation SOCIAL MEDIA Add to Any Platform Loading , MD, MS, Center for Human Reproduction Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: Topic Resources Vaginal itching (pruritus), discharge, or both result from infectious or noninfectious inflammation of the vaginal mucosa ( ), often with inflammation of the vulva (vulvovaginitis). Symptoms may also include irritation, burning, erythema, and sometimes dysuria (...) include Use of antibiotics (which may decrease lactobacilli) Alkaline vaginal pH due to menstrual blood, semen, or a decrease in lactobacilli Poor hygiene Frequent douching Pregnancy Diabetes mellitus An intravaginal foreign body (eg, a forgotten tampon or vaginal pessary) Etiology The most common causes vary by patient age (see table ). Children usually involves infection with GI tract flora (nonspecific vulvovaginitis). A common contributing factor in girls aged 2 to 6 yr is poor perineal hygiene

2013 Merck Manual (19th Edition)

583. Schistosomiasis

in and . With S. haematobium , ulcerations in the bladder wall may cause dysuria, hematuria, and urinary frequency. Over time, chronic cystitis develops. Strictures may lead to hydroureter and hydronephrosis. Papillomatous masses in the bladder are common, and squamous cell carcinoma may develop. Blood loss from both GI and GU tracts frequently results in anemia. Secondary bacterial infection of the GU tract is common, and persistent Salmonella septicemia may occur with S. mansoni . Several species, notably S (...) the likelihood of infection. Adult residents of endemic areas are more resistant to reinfection than children, suggesting the possibility of acquired immunity. Mass community-based or school-based treatment with praziquantel , education programs, and molluscicides to reduce snail populations are used to control schistosomiasis in endemic areas. Vaccine development is under way. Key Points Schistosoma is the only trematode that invades through the skin; about 207 million people are infected worldwide. When

2013 Merck Manual (19th Edition)

584. Efficacy and Safety of Tulobuterol Patch Combined With Tiotropium Bromide for Relieving Dyspnea Symptom of Chronic Obstructive Pulmonary Disease

of hyperthyroidism, hypertension, heart disease and severe arrhythmia, diabetes mellitus, who are not appropriate to useβ2 receptor agonist patients who have undergone pulmonary lobectomy or have tumor active tuberculosis patients people who got acute respiratory tract infection in a month or during screening phase allergic rhinitis patients glaucoma patients people who have diseases which may cause dysuria such as prostatic hypertrophy or bladder neck occlusion gestation, lactation and child-bearing age women

2011 Clinical Trials

585. The Cleveland Clinic experience with adult hypospadias patients undergoing repair: their presentation and a new classification system. Full Text available with Trip Pro

or pendulous) hypospadias (56.4%) and the others had more proximal (bulbar) hypospadias (43.6%). • Voiding symptoms (such as dysuria, weak stream, spraying, urgency, frequency) were the most common presenting complaint (50.9%) and overall symptom (81.8%). About half of patients underwent a two-stage urethroplasty (52.7%). • Based on their history of repair, patients were divided into three categories: I, patients who have undergone continuous multiple surgeries for repair with significant scarring (...) and tissue loss; II, delayed complications after an initially successful childhood repair; and III, no previous repair. Most patients were category I (58.2%); however, seven patients (12.7%) were category III. Balanitis xerotica obliterans (BXO) was more common in this subgroup compared with other categories (42.9% vs 8.3%, respectively, P= 0.037). In two of the three patients in category III with BXO, the stricture length was longer than 7 cm.• Adults with hypospadias represent a heterogeneous group

2011 BJU international

586. Phase III Study of Tolvaptan Tablet to Treat Cirrhosis Ascites

hemorrhage during the study; Heart failure (NYHA2) grade III or IV); Anuresis (daily urine volume is less than 100mL); Dysuria due to urinary tract stricture, urinary calculus, tumor in the urinary tract or other cause. Patients with history of : Alimentary tract hemorrhage within 10 days prior to screening; Cerebral accident suffered within 30 days prior to screening; Past history of hypersensitivity or idiosyncratic reaction to benzazepine derivatives (Benazepril). Patients with systolic pressure below (...) 90mmHg at screening; Patients with any of the following abnormal laboratory parameters at screening: Serum creatinine >1.5x upper limit of normal range; Serum Na+>145mmol/L (or higher than upper limit of normal range); Serum K+>5.5mmol/L; Patients with Child-pugh score3)>12; Patients who are unable to take medicine orally; Female patients who are pregnant, lactating, or who are at child-bearing age without using acceptable contraceptive means; Patients who received blood products including albumin

2011 Clinical Trials

587. GSK2251052 in Complicated Urinary Tract Infection

and during an operative procedure, when oral antibiotics are not indicated or in cases where the cUTI is suspected to be due to a pathogen resistant to current oral antibiotics and at least two of the following UTI symptoms including dysuria, frequency, urgency or suprapubic pain, with the presence of a complicating factor: Male gender; Current bladder instrumentation or indwelling urinary catheter that has to be removed two days before the end of IV study drug administration; Obstructive uropathy (...) ) on direct examination of a Gram-stained specimen of spun/unspun MSU or catheter urine. Subject is considered unlikely to survive the 4 6 week study period or has any rapidly progressing disease or immediately life-threatening illness (including acute hepatic failure, respiratory failure or septic shock). Subject has evidence of known or pre-existing severe hepatic disease (Child-Pugh score of B or C). Subject has a known baseline haemoglobin less than 10 g/dL ,haematocrit less than 30% and/or a known

2011 Clinical Trials

588. Brachytherapy Full Text available with Trip Pro

localised bruising, swelling, bleeding, discharge or discomfort within the implanted region. These usually resolve within a few days following completion of treatment. Patients may also feel fatigued for a short period following treatment. Brachytherapy treatment for cervical or prostate cancer can cause acute and transient urinary symptoms such as urinary retention, urinary incontinence or painful urination (dysuria). Transient increased bowel frequency, diarrhoea, constipation or minor rectal bleeding (...) being in close proximity with them. If permanent brachytherapy is used, low dose radioactive sources (seeds) are left in the body after treatment – the radiation levels are very low and decrease over time. In addition, the irradiation only affects tissues within a few millimeters of the radioactive sources (i.e. the tumour being treated). As a precaution, some people receiving permanent brachytherapy may be advised to not hold any small children or be too close to pregnant women for a short time

2012 Wikipedia

589. Chlamydia trachomatis Full Text available with Trip Pro

factors for genitourinary infections include unprotected sex with multiple partners, lack of condom use, and living in an urban area. Pulmonary infections can occur in infants born to women with active chlamydia infections, although the rate of infection is less than 10%. Ocular infections take the form of conjunctivitis or trachoma, both in adults and children. Trachoma is the primary source of infectious blindness in some parts of rural Africa and Asia and is a that has been targeted by the World (...) (genitals), pulmonary (lungs), and ocular (eyes). Genitourinary cases can include genital discharge, vaginal bleeding, itchiness (pruritus), painful urination (dysuria), among other symptoms. Often, symptoms are similar to those of a . Prevalence [ ] Three times as many women as men are diagnosed with genitourinary C. trachomatis infections. Women aged 15–19 have the highest prevalence, followed by women aged 20–24, although the rate of increase of diagnosis is greater for men than for women. Risk

2012 Wikipedia

590. Safety, Pharmacokinetics and Clinical Activity of Oral Rigosertib in Solid Tumors

prior dose. If two or more patients in any cohort experience DLT, then the maximum tolerated dose (MTD) will have been exceeded and no further dose escalation will occur. The MTD will be established as the immediate prior dosing level Identical rules will be applied to all cohorts of patients recruited to the study. A total of up to 24 patients may be treated at the MTD dose level in order to obtain data on the onset and severity of dysuria symptoms in approximately 12 patients including about 6 (...) in at least 1 dimension with longest diameter equal to or greater than 20 mm using conventional techniques (computed tomography [CT] scan or magnetic resonance imaging [MRI]) or equal to or greater than 10 mm with spiral CT scan. If female, has a negative screening for pregnancy. Women of child-bearing potential and men must agree to use adequate contraception prior to study entry (hormonal or barrier method of birth control; abstinence) and for the duration of study participation. Should a woman become

2010 Clinical Trials

591. Management of Urinary Tract Infections in Primary Care Facilities.

Ages Eligible for Study: 16 Years to 55 Years (Child, Adult) Sexes Eligible for Study: Female Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Females 16-55 years Dysuria Increased frequency of urination Exclusion Criteria: Pregnant Breastfeeding child < 1 month of age Diabetes Kidney disease Fever Poor general condition Backpain Abdominal pain Increased amount of vaginal secretions Vaginal itching or pain Urinary tract infection in the last four weeks Use of urinary catheter in the last

2010 Clinical Trials

592. Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting Full Text available with Trip Pro

Risk factors of HIV vertical transmission in a cohort of women under a PMTCT program at three peri-urban clinics in a resource-poor setting To identify the risk factors of HIV vertical transmission in pregnant women.Observational cohort study. Between 2002 and 2003, 479 HIV-infected pregnant women in a PMTCT (prevention of the mother-to-child transmission) program were followed up with their infants at delivery, until 15 months with infant HIV testing.Of these 281 infants had a definitive HIV (...) result by 15 months of age, and 31.7% of the infants become HIV infected. In univariate analysis the risk factor identified were presence of vaginal discharge, genital itchiness, genital ulcers, dysuria, abnormal breast and vaginal infections (Trichomonas, Bacteria vaginosis and Candida) in the mother at enrolment. In multivariate analysis vaginal infections risk ratio (RR) 1.72(1.03-2.88) and abnormal breast RR 4.36(2.89-6.58) were predictors of HIV vertical transmission.There is need to screen

2010 Journal of Perinatology

593. Mutations in HPSE2 cause urofacial syndrome. Full Text available with Trip Pro

Mutations in HPSE2 cause urofacial syndrome. Urinary voiding dysfunction in childhood, manifesting as incontinence, dysuria, and urinary frequency, is a common condition. Urofacial syndrome (UFS) is a rare autosomal recessive disease characterized by facial grimacing when attempting to smile and failure of the urinary bladder to void completely despite a lack of anatomical bladder outflow obstruction or overt neurological damage. UFS individuals often have reflux of infected urine from

2010 American Journal of Human Genetics

594. Nonoperative management of symptomatic urachal anomalies. (Abstract)

anomalies was performed from January 2002 to March 2008. Children with a draining umbilicus and no radiographic or surgical confirmation of a urachal anomaly were excluded.Fifteen patients with symptomatic urachal anomalies were identified. The average age was 3.5 years (4 weeks to 14 years). Symptoms included umbilical drainage (n = 10), abdominal pain (n = 6), omphalitis (n = 4), intraabdominal mass (n = 3), dysuria (n = 1), recurrent urinary tract infections (n = 1), and fever (n = 4). The diagnosis

2010 Journal of Pediatric Surgery

595. Dose Exploring and Setting Study for Tolvaptan to Treat Hepatic Cirrhosis With Ascites

: Hepatic encephalopathy (Coma scale Note 1) grade 2 or higher); Malignant ascites; Uncontrolled spontaneous bacterial peritonitis; Patients are likely to experience alimentary tract hemorrhage during the trial; Heart failure (NYHA cardiac function scale Note 2) stages 3 and 4); Anuria (daily urine volume below 100mL); Dysuria resulting from urethral stricture, calculus and tumors. Patients with the following medical history: Alimentary tract hemorrhage within 10 days prior to screening; Cerebrovascular (...) accident within 1 month prior to screening; Gout attack within 1 month prior to screening; Past allergy or hypersensitive reactions to benzodiazepines (e.g. benazepril hydrochloride) Systolic pressure below 90mmHg at screening; Patients with the following abnormalities in laboratory examinations at screening: Serum creatinine exceeds 2.5X upper limits of normal, serum Na+>145mmol/L (or exceeds upper limits of normal), serum K+>5.5mmol/L, uric acid>8.0mg/dL (476μmol/L), Child-pugh scale greater than 12

2010 Clinical Trials

596. Multiple-dose Pharmacokinetics Study of Tolvaptan Tablets in Chinese Patients With Hepatocirrhosis

actions and safety of Tolvaptan tablets administered orally (15 mg daily) for consecutively 7 days in Chinese adult patients with confirmed Child-Pugh Class B(score 7-9) hepatocirrhosis (accompanied by ascites). Trial Design: Open, single-center, multi-dose pharmacokinetics study Study population: Chinese adult patients with confirmed Child-Pugh Class B (score 7-9) hepatocirrhosis (accompanied by ascites) Dosage and mode of administration of investigational product: Oral administration of 1 tablet (...) ); Malignant ascites; Spontaneous bacterial peritonitis; Likely to have gastrointestinal bleeding during the study period; Heart failure (NYHA Note 2 Class Ⅲ andⅣ); Anuria (daily urine output below 100mL); Dysuria induced by urinary tract stenosis, calculus, or tumor. Patients with any of the following history: With gastrointestinal bleeding within 10 days prior to screening; With cerebrovascular accident within 1 month prior to screening; With gout attack within 1 month prior to screening; With allergy

2010 Clinical Trials

597. Efficacy of Combination Therapies for Gonorrhea Treatment

). Clinical Profile of Treatment Failures. [ Time Frame: 10-17 days ] For treatment failures (i.e., participants with positive culture at cervix/urethra 10-17 days after treatment), number participants with clinical symptoms (vaginal/urethral discharge, dysuria, dyspareunia) at 10-17 days. Resolution of Symptoms and Signs (Clinical Cure) [ Time Frame: 10-17 days after treatment. ] Number of participants whose gonorrhea-related symptoms (e.g. vaginal/urethral discharge, dysuria, dyspareunia) present (...) or not associated with study product. Eligibility Criteria Go to Information from the National Library of Medicine Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Layout table for eligibility information Ages Eligible for Study: 15 Years to 60 Years (Child

2009 Clinical Trials

598. Anxiety and Recurrent Abdominal Pain in Children

and tolerability. Condition or disease Intervention/treatment Phase Abdominal Pain Anxiety Drug: Citalopram Phase 2 Phase 3 Detailed Description: This study aims to determine the relative efficacy, tolerability, and safety of the citalopram in the treatment of pediatric functional recurrent abdominal pain (FAP) in children and adolescents ages 7 to 18 years, inclusive. The goal is to recruit and randomize 100 subjects to citalopram or placebo. Secondary aims include to determine if citalopram is superior (...) on the Children's Global Assessment Scale Residing with a primary caretaker (i.e., parent, legal guardian, relative functioning as a parent, or foster parent) who has known the child well for at least 6 months prior to study entry and has legal authority to consent to participation. Exclusion Criteria: Physical disease sufficient to explain the subjective distress and functional impairment suffered by the subject. FAP with atypical features: Abnormal abdominal or rectal examination GI bleeding (i.e., hematest

2009 Clinical Trials

599. New Tissue Bulking Agent (Polyacrylate Polyalcohol) for Treating Vesicoureteral Reflux: Preliminary Results in Children. (Abstract)

New Tissue Bulking Agent (Polyacrylate Polyalcohol) for Treating Vesicoureteral Reflux: Preliminary Results in Children. We report the preliminary results of endoscopic treatment of vesicoureteral reflux in children using polyacrylate polyalcohol copolymer.We performed a prospective multicenter review of pediatric patients treated with subureteral injection of a new nonabsorbable substance. Only patients with 1 year of followup were included.A total of 83 patients underwent injection (...) 16 to 24). Complications after injection included dysuria in 6 patients (9.8%), fever in 3 (4.9%) and lumbar pain in 4 (6.6%). Reflux was eliminated in 78 renal units (88.6%), decreased to grade I in 6 (6.8%) and persisted in 4 (4.5%). Ureteral obstruction developed in 1 patient and was treated operatively. Overall success rate was 83.6%.Polyacrylate polyalcohol copolymer can be used to treat vesicoureteral reflux with comparable efficacy to other substances currently used, with a low rate

2009 Journal of Urology

600. Recurrent Abdominal Pain in Childhood Urolithiasis. (Abstract)

Recurrent Abdominal Pain in Childhood Urolithiasis. Our goal was to establish the clinical presentation and features of pain attacks in children with recurrent abdominal pain (RAP) and urolithiasis.We compared the rate of previous appendectomy among 100 consecutive patients with that of 270 control subjects. We also compared the frequency of pain attacks with that reported by children with functional or organic gastrointestinal RAP.Fifty-three patients had no history of dysuria or gross (...) should be considered in children with RAP who have a family history of urolithiasis and/or infrequent pain attacks, even when dysuria and hematuria are lacking, and in younger children even when pain is not lateral.

2009 Pediatrics

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>